A study of thromboembolic events in patients of advanced stage lung cancer treated with platinum based chemotherapy.
Not Applicable
- Conditions
- Health Condition 1: null- Advanced stage non small cell lung cancer (NSCLC) patients treated with platinum based chemotherapy.
- Registration Number
- CTRI/2014/11/005227
- Lead Sponsor
- Tata Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 167
Inclusion Criteria
INCLUSION CRITERIA:
Lung cancer patients (age >18 years) who are started on platinum based chemotherapy.
Exclusion Criteria
EXCLUSION CRITERIA:
1. Age <18 years
2. Patients in whom therapy is discontinued prior to completion of 6 weeks due to any reason.
3. Presence of any thromboembolic event before start of chemotherapy including deep venous thrombosis (DVT), pulmonary embolus, cerebrovascular accident, and unstable angina/myocardial infarction (MI).
4.Patients with bleeding diathesis, inherited coagulopathy, and those requiring therapeutic anticoagulation, regular nonsteroidal anti-inflammatory drugs, and aspirin.
5. Patients receiving angiogenesis inhibitor drug- bevacizumab.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method